One Fraction Simulation-Free Treatment With CT-Guided Stereotactic Adaptive Radiotherapy for Patients With Oligometastatic and Primary Lung Tumors

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

10 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-02-26

Study Completion Date

2025-08-05

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Stereotactic body radiotherapy (SBRT) has become a standard of care for medically inoperable or high-risk operable early-stage non-small cell lung cancer (NSCLC) patients. It is also increasingly used to treat lung metastases in patients with oligometastatic disease. While SBRT is a powerful tool for the treatment of lung tumors, access to specialized treatment can be limited for patients who live far away from a treatment center. Geographic accessibility can be limiting even for patients receiving one fraction lung SBRT, as the typical consult, CT simulation, and one-fraction treatment workflow is typically at least two to three weeks from start to finish, with a minimum of three in-person appointments.

In this study, a high-quality cone beam CT (CBCT) on-board imaging platform (HyperSight; Varian Medical Systems, Palo Alto, CA) will be coupled with advanced motion management and treatment techniques as well as Ethos (Varian Medical Systems, Palo Alto, CA) daily online adaptation to simulation-free workflow for one fraction SBRT. This has the potential to reduce the time it takes a patient to be cured of their lung tumor from two to three weeks to two to three hours. In this novel workflow, patients will undergo telephone/online consent followed by a diagnostic scan-based pre-plan for one fraction SBRT. On the morning of treatment, a brief follow-up appointment will be followed by treatment on the HyperSight/Ethos platform. Patients will be treated using a simulation-free workflow. A HyperSight Thorax Slow protocol CBCT will be acquired for study purposes, and then the patient will be treated with online adaptive CBCT-guided radiotherapy on the Ethos/HyperSight platform. Treatment delivery will take place following contouring and treatment planning. Patients will undergo standard of care simulation imaging in parallel for comparison.

The purpose of this study is to evaluate the feasibility of a ONE fraction Simulation-free Treatment with CT-guided stereotactic adaptive radiotherapy for Oligometastatic and Primary lung tumors (ONE STOP) workflow for patients with small, peripheral primary or oligometastatic lung tumors.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

MR-informed Stereotactic Radiotherapy for Treatment of Ultracentral Lung Tumours Utilising a Dedicated MR-simulator for Daily Adaptation Followed by CBCT-guided Treatment Delivery

NCT06815289

Primary Lung Cancer or Secondary Lung Metastases

RECRUITING NA

Stereotactic Body Radiation Therapy in Stage II/III Non Small Cell Lung Cancer

NCT01657617

Lung Cancer

COMPLETED NA

Stereotactic Body Radiation Therapy in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer That Can Be Removed By Surgery

NCT00551369

Lung Cancer

COMPLETED PHASE2

Irradiation of Large Lung Tumors or Two or More Lung Metastases Simultaneously

NCT01543672

Lung Cancer Metastatic Lung Cancer

COMPLETED PHASE1/PHASE2

Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer

NCT06686771

Non-small Cell Lung Cancer

RECRUITING PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lung Cancer Oligometastatic Lung Tumor

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

One Fraction SBRT

Consenting and eligible patients will receive a prescription dose of 25-34 Gy in one fraction with adaptation based on daily anatomic changes as per clinical standard of care.

Group Type EXPERIMENTAL

One fraction stereotactic body radiotherapy

Intervention Type RADIATION

Radiotherapy will consist of one-fraction SBRT using the Ethos linear accelerator and online adaptive treatment planning system.

HyperSight

Intervention Type DEVICE

HyperSight is a novel on-board imaging platform equipped with rapid-acquisition high-quality CBCT imager capable of acquiring images sufficient for both simulation and treatment.

Ethos

Intervention Type DEVICE

Ethos is a unique ring-gantry CT-guided linear accelerator notable for having a dedicated artificial intelligence treatment planning system to allow for online adaptive radiotherapy.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

One fraction stereotactic body radiotherapy

Radiotherapy will consist of one-fraction SBRT using the Ethos linear accelerator and online adaptive treatment planning system.

Intervention Type RADIATION

HyperSight

HyperSight is a novel on-board imaging platform equipped with rapid-acquisition high-quality CBCT imager capable of acquiring images sufficient for both simulation and treatment.

Intervention Type DEVICE

Ethos

Ethos is a unique ring-gantry CT-guided linear accelerator notable for having a dedicated artificial intelligence treatment planning system to allow for online adaptive radiotherapy.

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

SBRT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* One of the following diagnoses:

* Histologically or radiographically diagnosed stage I-IIA (AJCC, 8th ed.) non-small cell lung cancer .

* Clinical AJCC stage I defined as stage 1A1 (T1a1N0M0, T1a tumor less than or equal to 1 cm), stage 1A2 (T1bN0M0, T1b tumor between 1 and 2 cm), and stage 1A3 (T1cN0M0, T1c tumor between 2 and 3 cm).
* Clinical AJCC stage IB defined as T2aN0M0, T2a tumor between 3 and 4 cm.
* Clinical AJCC stage IIA defined as T2bN0M0, T2b tumor between 4 and 5 cm.
* Oligometastatic lung tumor secondary to a primary cancer of any type/histology. Oligometastatic patients may include patients with:

* 1-5 sites of metastatic disease with at least one lung lesion intended to be treated with SBRT
* More than 5 sites of metastatic disease with oligo-progressive disease in the lung intended to be treated with SBRT.
* Lesions must be small and peripheral.

* Small is defined as max tumor dimension of 5 cm or less.
* Peripheral is defined as greater than 2 cm from the proximal bronchial tree/mediastinum.
* Tumors and anatomy amenable to one-fraction lung SBRT confirmed by meeting of one-fraction lung SBRT target and constraint metrics on a diagnostic-scan based preplan.

* Patients who do not meet this criterion will be screen fails and triaged to the standard lung SBRT workflow and treated off trial.
* Lesions must have a maximum superior to inferior motion of 1 cm on 4D-CT imaging.

* Patients who do not meet this criteria will be screen fails and triaged to the standard lung SBRT workflow and treated off trial.
* At least 18 years of age.
* Able to understand and willing to sign an IRB approved written informed consent.

Exclusion Criteria

* Past history of radiotherapy within the projected treatment field of any of the disease sites to be treated by ONE STOP SBRT.
* Pregnant and/or breastfeeding. Patient must have a negative pregnancy test within 14 days of ONE STOP SBRT.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No